Evaluating Outcomes of Sacral Neuromodulation in Patients With Multiple Sclerosis
Neurourology and Urodynamics · 2026-08 · 45 (6) · 1161-1167
DOI: 10.1002/nau.70292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurourology and Urodynamics, online erschienen am 16.04.2026. Verfasst von Murat Yavuz Koparal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Multiple Sclerosis, Electric Stimulation Therapy, Device Removal, Lumbosacral Plexus. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
To evaluate the revision and removal rates of sacral neuromodulation (SNM) in patients with multiple sclerosis (MS) using a large national administrative dataset.
Methods
This was a retrospective cohort study using the Premier Healthcare Database. There were 13 913 patients analyzed between the years of 2006 and 2022), 218 of whom had diagnosis of MS. Patients were categorized into two groups as with MS and without any neurological disorders including MS (controls). The primary outcome was the relationship of MS on the 1‐ and 5‐year device revision/removal rates. Secondary outcomes were associated complication rates within 1 year and beyond 1 year, the association between type of antibiotic prophylaxis and infectious complications.
Results
Patients with MS had similarly low rates of mechanical (within 1 year 1.8% vs. 2.1%; p = 0.98, and beyond 1 year 2.8% vs. 4.5%; p = 0.28), infectious (within 1 year 1.4% vs. 0.84%; p = 0.62, and beyond 1 year 0% vs. 0.29%; p = 0.88), and other complications (within 1 year 0.46% vs. 0.73%; p = 0.95, and beyond 1 year 0.46% vs. 0.93%; p = 0.71) within and beyond 1 year compared to controls, respectively. There was no statistically significant difference in revision/removal rates at 1 and 5 years between MS (11.2% and 29.9%) and for control patients (8.1% and 26.9%), respectively. In multivariable Cox proportional hazards models, MS was not found to be associated with removal/revision.
Conclusion
Our results suggest that a diagnosis of MS does not appear to impact SNM associated revision/removal rates and is associated with similarly low rates of complications compared to patients without any neurologic condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
- Case Western Reserve University, Cleveland, Ohio, USA.
- Department of Urology, Gazi University, Ankara, Turkiye.
Zitieren
APA
Koparal, M. Y., Rhodes, S., Sheyn, D., & Hijaz, A. (2026). Evaluating Outcomes of Sacral Neuromodulation in Patients With Multiple Sclerosis. Neurourology and Urodynamics, 45(6), 1161-1167. https://doi.org/10.1002/nau.70292
Vancouver
Koparal MY, Rhodes S, Sheyn D, Hijaz A. Evaluating Outcomes of Sacral Neuromodulation in Patients With Multiple Sclerosis. Neurourology and Urodynamics. 2026;45(6):1161-1167. doi:10.1002/nau.70292
BibTeX
@article{Koparal2026,
author = {Koparal, Murat Yavuz and Rhodes, Stephen and Sheyn, David and Hijaz, Adonis},
title = {Evaluating Outcomes of Sacral Neuromodulation in Patients With Multiple Sclerosis},
journal = {Neurourology and Urodynamics},
year = {2026},
volume = {45},
number = {6},
pages = {1161--1167},
doi = {10.1002/nau.70292}
}
EUVIMED